Mindmed Announces Voting Results for Annual General and Special Meeting

Rhea-AI Summary

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the results of its annual general and special meeting of shareholders held on June 1, 2022. All five management nominees were successfully elected as directors, with percentages of votes ranging from 89.04% to 96.72%. KPMG LLP was appointed as the company's auditor for the coming year. Additionally, shareholders approved an alteration to the company's share structure, eliminating Multiple Voting Shares and re-designating Subordinate Voting Shares as Common Shares. This strategic move aims to streamline the company's capital structure.

Positive

• Successful election of five management nominees with strong voting percentages, indicating shareholder confidence.
• Appointment of KPMG LLP as auditor, suggesting oversight stability.
• Approval of share structure alteration to enhance simplicity and accessibility for investors.

Negative

• None.

NEW YORK, June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting").

Election of Directors

The five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows:

Name of Nominee	Votes For		Votes Withheld
	Number of Votes	Percentage of Votes	Number of Votes	Percentage of Votes
Carol A. Vallone	66,244,518.68	89.04%	8,146,247.47	10.95%
Andreas Krebs	71,955,691.97	96.72%	2,435,074.18	3.27%
Brigid A. Makes	65,578,489.16	88.15%	8,812,276.99	11.84%
Robert Barrow	70,713,915.05	95.05%	3,676,851.10	4.94%
Dr. Miri Halperin Wernli	70,671,060.87	94.99%	3,719,705.28	5.00%

Appointment of Auditor

At the Meeting, KPMG LLP was appointed as the auditor of the Company for the ensuing year and the directors were authorized to fix the remuneration to be paid to the auditor.

Alteration to the Company's Share Structure

At the Meeting, shareholders approved the alteration to the Company's share structure to eliminate the Multiple Voting Shares of the Company and re-designate the Subordinate Voting Shares as Common Shares of the Company.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media: media@mindmed.co
For Investors: ir@mindmed.co

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-voting-results-for-annual-general-and-special-meeting-301559628.html

SOURCE Mind Medicine (MindMed) Inc.

FAQ

What were the voting results for MindMed's annual meeting on June 1, 2022?

All five management nominees were elected as directors, with votes ranging from 89.04% to 96.72% in favor.

Who was appointed as the auditor for MindMed for the next year?

KPMG LLP was appointed as the auditor for MindMed at the annual meeting.

What changes were made to MindMed's share structure on June 1, 2022?

Shareholders approved the elimination of Multiple Voting Shares and re-designated Subordinate Voting Shares as Common Shares.

What is the stock symbol for Mind Medicine?

Mind Medicine trades on NASDAQ under the symbol MNMD.